Member Info for PDMSPiper

“Most long-term studies found that IgG waned over time (typically detectable up to at least a year) while others found detectable levels of IgG three years post symptoms onset.”

Coronavirus antibody immunity scientific paper14 Jun 2020 06:57

“A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease“

“Key findings:
We have presented a broad, comprehensive review of multiple aspects of the literature on antibody immunity to coronaviruses. We identified a number of key findings. The median time to detection was similar across different antibodies for SARS-CoV-1 (12 days; IQR 8-15.2 days) and SARS-CoV-2 (11 days; IQR 7.25-14 days), but longer for MERS-CoV (16 days; IQR 13-19 days). Most long-term studies found that IgG waned over time (typically detectable up to at least a year) while others found detectable levels of IgG three years post symptoms onset. Antibody kinetics varied across the severity gradient with longer durations of detectable antibody associated with more severe symptoms. Human challenge studies with HCoV indicate that serum and mucosal immune responses (serum IgG, IgA, neutralizing titer, mucosal IgA) provide possible correlates of protection from infection and disease. However, repeat human challenge experiments with single HCoV suggest individuals can be infected with the same HCoV one year after first challenge, but with possible lower severity. There is cross-reactivity within but minimal reactivity between Alpha- and Beta-CoVs. While endemic HCoVs rarely induce cross-reactive antibodies against emerging HCoVs, SARS-CoV-1 and MERS-CoV stimulate antibodies induced by prior HCoV infections.”

https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full.pdf

Interesting little video report from the Indian Economic Times. .......

“Rapid antibody testing expanded: Is India looking at COVID-immune certificates?

The Indian Council of Medical Research has asked public and private hospitals, PSUs and other offices to conduct IgG antibody tests on employees to get them to work. The ICMR says such tests will help in removing the fear and anxiety of health care worders”

https://m.economictimes.com/industry/healthcare/biotech/rapid-antibody-testing-expanded-is-india-looking-at-covid-immune-certificates/videoshow/76571698.cms

If people were getting reinfected then the media would be all over it and they’d be popping up all over the bbc news and sky and the papers saying they’ve had it twice. The media love a good sensational scare story and they all know it would be a major scoop if they can bring forward a case of a verified reinfection for the front page but they can’t find any.

Over 6.5 million recovered patients globally and the entire worlds media can’t find any twice infected patients for their front pages. None.

Chuggley - IMO it is because a compliant and obedient population might still be required for future lockdowns.
As soon as they come out and verify or admit to immunity after infection then certain hero johnnies will be running around giving the cops two fingers and refusing to comply because they’ve had s positive test and recovered.
They are not at that stage yet but they will be in future when they decide the strategy will no longer be lockdowns and they need as many of us back in normal life as possible and that time is rapidly approaching imo. A bit more contagion from pubs etc in the next couple of months and they’ll start mass antibody testing for immunity.
Gov strategy on herd immunity has always governed RTC newsflow for when the time is right and will continue to do so imo.

We already know the body produces antibodies to fight Covid 19, hence the effectiveness of convalescent plasma transfusion therapy. Current Patients receiving plasma from recovered patients high in antibodies are seeing strong rates of recovery, resistance and immunity.

https://www.nytimes.com/2020/04/24/smarter-living/coronavirus-convalescent-plasma-antibodies.html

The only question now is how long immunity lasts. Six months and counting, over 6 million recovered patients globally and still not one verified reinfected patient.

Only a matter of time before the period of immunity is deemed sufficient to issue recovered people with digital certificates to go back to work and resume normal life etc.

Current estimates are 80% of us are going to get it at some stage so no point having everybody locked down unnecessarily. They can’t afford to do that again so it’s on to stage 2 now.

Yes Woody, with our suite of products and more coming online I see a market cap of £280-300Million as very achievable over the next 6 months.

Of the big three you mention ODX are by far the most likely to breach all time highs again in coming weeks. I’d expect to be over the quid going into the autumn if newsflow on orders comes good.

NCYT - I really think the market has lost interest in lab tests. It’s all about rapid poc test stick cassettes now. NCYT has its day.

AVCT - Still got no products and have failed to commercialize one viral application for their affirmers over the last five years. It all smells a bit Dodgey over there to me.
With 249 million shares in issue Avacta now need a market cap of £522Million just to get back to their all time high of £2.10 where investors got ramped into an unsupported spike with no saleable product. I can’t see it happening but we watch with interest.

An incoherent strategy is the strategy. Spain is the same. My neighbors say it’s all “contradictorio”.

Every gov has an incoherent strategy that makes no sense to joe public because we’re supposed to be confused and unsure as to what we do. That way we don’t all go back to normal at once.

There is coherence in the incoherence. It’s developed by scientists. They know better than us. If we’d been left to our own devices 100’s of thousands would have died and we’d have been dyeing in the streets and at home as emergency services could not cope.

No worries Olderandwiser, you stick to lapping up that Yellow Jersey Avacta Jam that’s coming tomorrow.

As a big Avacta shareholder and tamper, the history you should be looking into is Turner Pope and Yellow Jersey.

I guarantee you the Yellow Jersey produced Avacta PR machine will continue to produce nothing but jam on the fictitious “Avacta Covid Test” and the interviews and chat from the company will turn more towards ramping the cancer research until the penny finally drops with gullible shareholders that you aren’t actually getting a Covid Test.

Yellow jersey are past masters at keeping investors on the hook with Jam while changing focus. They’ve done it time and time again.

I’ll watch it play out. You won’t showing up on this board for much longer Older, I can guarantee that.

Breaking news in Delhi Economic Times. Article only 4 hours old.

Delhi pushes Antibody tests for unlock 2.0

https://m.economictimes.com/news/politics-and-nation/delhi-pushes-antibody-tests-for-unlock-2-0/articleshow/76740494.cms

Strong Buy!

With a range of antibody tests, both rapid poc and Elisa, antigen tests due in months and the existing CD4 tests it looks like Omega are in a Fantastic position.

What other company at this low Mcap has all these tests due within months. None. Only omega. A market leading position in my opinion.

10 out of 10 patients had CoV-2-specific CD4 cells.

This could be huge for the Omega Visitect CD4 test if it can be adapted to pick up these Covid CD4 cells.

Break out the Visitect CD4 test to detect Covid CD4 cells.

“Here, we studied 10 COVID-19 patients who required admission to an intensive care unit and detected SARS-CoV-2-specific CD4+ and CD8+ T cells in 10 out of 10 and 8 out of 10 patients, respectively.”

https://immunology.sciencemag.org/content/5/48/eabd2071.full

I don’t lead anything. I haven’t posted all day.

I have no idea what the revenue would be. Have to wait and see.

Interesting little video report from the Indian Economic Times. .......

“Rapid antibody testing expanded: Is India looking at COVID-immune certificates?

The Indian Council of Medical Research has asked public and private hospitals, PSUs and other offices to conduct IgG antibody tests on employees to get them to work. The ICMR says such tests will help in removing the fear and anxiety of health care worders”

https://m.economictimes.com/industry/healthcare/biotech/rapid-antibody-testing-expanded-is-india-looking-at-covid-immune-certificates/videoshow/76571698.cms

Mologic fully expected to supply the Elisa tests to U.K. gov but they weren’t ready at the time and omega facility at Littleport was not geared up for production.
Gov went with Roche Elecsys and bought 10 mill. The test has been heavily criticized. The letter from the scientists and the panorama program was basically bashing the Roche test and lack of thorough validation by PHE. It was rushed through as gov were under pressure.

Elisa test is now ready. CE marked. Omega are fully geared up at Littleport and have produced validation batches. The Elisa tests are currently being assessed by PHE and various university scientific bodies. The development of the Mologic Elisa tests was gov funded. Boris has connections with Mologic and has visited their labs.

With a decent result from the validation bodies and omega scaling up production at Littleport, it wouldn’t surprise me at all if we get a surprise U.K. Government order for these Mologic Elisa tests. Surprise value accretive events out of the blue that nobody expected are always by far the best for boosting the share price. :-)

GLA.

Oh ffs Dibs give it a rest with the bull****. There’s no way they are going to drop “development” of anything. Most of the development cost is being borne by others anyway. Total scare mongering bull.
And give it a rest pretending that you’re some sort of market soothsayer with the perfect entry and exit. You forget to mention that you’ve been sat in this stock for 4 years going nowhere before Covid and have spat your dummy before blaming the bod for your poor judgement. Hardly a great entry, 4 years going nowhere. As for your exit, you didn’t sell on the Sky interview, you totally missed the top at 87 and sold out using illegal insider trading at 58 after applying for the placing which you then didn’t get.
Give it a rest Dibs ya sad melt.

The new UK-RTC AbC-19 lateral flow test is for IgG antibodies to the SARS-COV-2 virus.

This scientific paper says IgG antibodies for similar Coronaviruses including SARS-COV-1 are typically detectable between one and three years after infection.

As for immunity, there has been over 10 million infections globally, 9.5Million recovered patients. Not one verified reinfected patient has yet been brought forward anywhere in the world.

We’ll be told that antibodies provide immunity when it suits gov strategies and they no longer need us fully compliant in regard to further lockdown regulations.

This is the scientific paper you refer to on antibodies and immunity and the key point summary from it...

Coronavirus antibody immunity scientific paper14 Jun 2020 06:57

“A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease“

“Key findings:
We have presented a broad, comprehensive review of multiple aspects of the literature on antibody immunity to coronaviruses. We identified a number of key findings. The median time to detection was similar across different antibodies for SARS-CoV-1 (12 days; IQR 8-15.2 days) and SARS-CoV-2 (11 days; IQR 7.25-14 days), but longer for MERS-CoV (16 days; IQR 13-19 days). Most long-term studies found that IgG waned over time (typically detectable up to at least a year) while others found detectable levels of IgG three years post symptoms onset. Antibody kinetics varied across the severity gradient with longer durations of detectable antibody associated with more severe symptoms. Human challenge studies with HCoV indicate that serum and mucosal immune responses (serum IgG, IgA, neutralizing titer, mucosal IgA) provide possible correlates of protection from infection and disease. However, repeat human challenge experiments with single HCoV suggest individuals can be infected with the same HCoV one year after first challenge, but with possible lower severity. There is cross-reactivity within but minimal reactivity between Alpha- and Beta-CoVs. While endemic HCoVs rarely induce cross-reactive antibodies against emerging HCoVs, SARS-CoV-1 and MERS-CoV stimulate antibodies induced by prior HCoV infections.”

https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full.pdf

Dibs knows full well this is great value. It’s disingenuous lying I have a problem with. Dibs fully intends to buy back in here at some point but isn’t ready to do so yet.
Well now we know if it goes over 58 his strategy has failed and we’ll be waving him goodbye.
Traders who think they’re Gordon gecko rarely swallow their pride and buy back higher. That’s why he’s worried. Clocks ticking dibs. Whatever he’s currently ramping he’s most probably selling it and will be buying back in here.
Value here is too glaringly obvious to ignore.

My guess is after the open offer is closed at midday Friday and PIs that need to sell some to take their allocation is finished then we’ll start to move up again.
Plus, news on the Mologic tests could drop anytime.
Expecting an RNS update on the Mologic Elisa Antibody Test any day now. PHE validation and possibly scale up of production at Littleport. Due any day.